Recombinant Human DHH Protein

來源: 發(fā)布時(shí)間:2024-04-26

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS?CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 .The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Before binding to the ACE-2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy. Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE-2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy.  透明質(zhì)酸酶,英文名稱Hyaluronidase,一類能夠降低體內(nèi)透明質(zhì)酸活性的酶的總稱,結(jié)構(gòu)上由4個(gè)相同亞基構(gòu)成。Recombinant Human DHH Protein

Recombinant Human DHH Protein,標(biāo)準(zhǔn)物質(zhì)

CD19蛋白在B細(xì)胞和體液免疫反應(yīng)中起著作用。成熟B細(xì)胞對(duì)抗原刺激、胚芽中心發(fā)育和抗體親和性成熟的反應(yīng)能力是必需的。CD19已成為血液學(xué)和實(shí)體的有前途的靶點(diǎn)。產(chǎn)品性質(zhì)同義詞CD19;B4;CVID3;Leu-12;MGC12802工會(huì)編號(hào)P15391來源生化重組人CD19蛋白表達(dá)于HK293細(xì)胞,標(biāo)記于C-端。它含有金屬1-Lys291。分子量重組cd19由283個(gè)氨基酸組成,預(yù)測分子質(zhì)量為31.6kda。純潔90%由社會(huì)發(fā)展秘書處----政策和兩性平等局確定。內(nèi)用Lal法測定每一種蛋白質(zhì)。公式化用0.22腔形過濾液對(duì)PBS進(jìn)行凍干。凍干前添加5%-8%海藻糖、甘露醇和0.01%TWEen80作為保護(hù)劑。重建離心管打開前。建議將其重組為100克/毫升以上的濃度。在蒸餾水中溶解凍干蛋白。Recombinant Mouse TIGITProtein,hFc TagCX3CL1用作粘附分子,而兩種形式都是表達(dá)CX3CR1的靶細(xì)胞的化學(xué)吸引力。

Recombinant Human DHH Protein,標(biāo)準(zhǔn)物質(zhì)

Recombinant Human ACE2/ACEH Protein,hFc Tag性能參數(shù),分子別名(Synonyms)ACE2;ACEH;ACE-2表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)HumanACE2/ACEHProteinisexpressedfromHEK293withhFctagattheC-Terminus.ItcontainsGln18-Ser740.[Accession|Q9BYF1-1]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof109.2kDa.Duetoglycosylation,theproteinmigratesto115-130kDabasedonSDS-PAGEresult.Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.活性(Activity)ELISAData:ImmobilizedSARS-COV-2SpikeS(B.1.1.529/Omicron)Trimer,HisTagat1μg/ml(100μl/well)ontheplate.DoseresponsecurveforHumanACE2,hFcTagwiththeEC50of13.7ng/mldeterminedbyELISA.制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.

CD30,又稱KI抗原和Tnfrsf8,是一種120kdaI型跨膜糖蛋白,屬于tnf受體超家族。成熟的人CD30由一個(gè)361AA細(xì)胞外域(ECD)和六個(gè)富含半胱氨酸的重復(fù),28AA跨膜段和188AA細(xì)胞質(zhì)域。相比之下,小鼠和大鼠CD30缺乏90AA的ECD,并且只包含三個(gè)富含半胱氨酸的重復(fù)。在ECD的共同區(qū)域內(nèi),人CD30與小鼠CD30和大鼠CD30的序列認(rèn)同率分別為53%和49%。人類CD30的交替剪接產(chǎn)生一個(gè)等形,包括細(xì)胞質(zhì)域的C132AA。CD30通常在抗原細(xì)胞和B細(xì)胞上表達(dá)。但是,它在霍奇金氏病(紅-斯特恩伯格細(xì)胞上)、其他淋巴瘤、慢性炎癥中,以及自體免疫。CD30與CD30配體/tnfsf8結(jié)合,TH細(xì)胞、單核細(xì)胞、粒細(xì)胞和髓質(zhì)胸腺上皮細(xì)胞上表達(dá)。產(chǎn)品性質(zhì)別名CD30;CD30KI-1;CD30Lreceptor;TNFRSF8;D1S166EKi-1;CD30KI-1工會(huì)編號(hào)P28908-1表達(dá)區(qū)間及表達(dá)系統(tǒng)重組的人CD30/Tnfrsf8蛋白表達(dá)于在C-端有標(biāo)記和AVI標(biāo)記的HK293細(xì)胞。它含有……。分子量大約41.3公里。由于糖基化,蛋白質(zhì)遷移到70-100kda基于三聯(lián)頁面結(jié)果。純度SDS-PAGE和高效液相色譜法測定的95%。內(nèi)分泌腺衍生的血管內(nèi)皮生長因子(EG-VEGF),也稱為(PK1),是分泌蛋白的原蛋白蛋白家族的成員。

Recombinant Human DHH Protein,標(biāo)準(zhǔn)物質(zhì)

透明質(zhì)酸酶活力單位(Unitdefinition)基于USP透明質(zhì)酸酶參照標(biāo)準(zhǔn),即每分鐘在37℃,pH5.7的2mL反應(yīng)液中引起OD6000.330個(gè)變化定義為一個(gè)活力單位。抑制劑(Inhibitor)Fe2+,F(xiàn)e3+,Zn2+,Cu2+,肝素,金精三羧酸,硫酸,硝酸,乙?;该髻|(zhì)酸,硫酸纖維素酯,膽汁等結(jié)構(gòu)式(Structure)運(yùn)輸和保存方法冰袋運(yùn)輸。-20℃保存,兩年有效。溶液配制溶于0.02MPBS(pH7.0),含77mMNaCl和0.01%BSA,濃度為1mg/mL。現(xiàn)配現(xiàn)用。該產(chǎn)品儲(chǔ)存液不穩(wěn)定,使用時(shí)建議現(xiàn)配現(xiàn)用。為了您的安全和健康,請(qǐng)穿實(shí)驗(yàn)服并戴一次性手套操作。重組腸激酶(rEK)是一種高純度的重組牛腸激酶輕鏈片段,氨基酸序列與牛腸激酶輕鏈一致,有著酶切位點(diǎn)。Bradykinin (1-7)

通過研究,CDNF可防止6-羥基多巴胺(6-OHDA)誘導(dǎo)的多巴胺能神經(jīng)元變性,這可能對(duì)帕金森氏病有益。Recombinant Human DHH Protein

產(chǎn)品描述纖維蛋白原(Fibrinogen,F(xiàn)g),即凝血因子I,分子量約340kDa,由α、β、γ三對(duì)不同多肽鏈組成,多肽鏈間以二硫鍵相連。α鏈分子量63.5kDa,β鏈分子量56kDa,γ鏈分子量47kDa,纖維蛋白原約含4%碳水化合物。纖維蛋白原參與凝血的原理:在凝血酶作用下,α鏈與β鏈分別釋放出A肽與B肽,生成纖維蛋白單體。在此過程中,由于釋放了酸性多肽,負(fù)電性降低,單體易于聚合成纖維蛋白多聚體,但此時(shí)單體之間借氫鍵與疏水鍵相連,尚可溶于稀酸和尿素溶液中。進(jìn)一步在Ca2+與活化的ⅩⅢ因子作用下,單體之間以共價(jià)鍵相連,則變成穩(wěn)定的不溶性纖維蛋白凝塊,完成凝血過程。來源于不同物種(如來源于牛、貓、狗、豚鼠、人、綿羊、小鼠和大鼠等)的纖維蛋白原具有相似的結(jié)構(gòu)和性質(zhì)。因此,一般來源于一種哺乳動(dòng)物的纖維蛋白原可與其他來源的凝血酶交叉反應(yīng),相反地來自一種哺乳動(dòng)物蛋白的凝血酶液也可注入多種動(dòng)物,發(fā)生凝血反應(yīng)。Recombinant Human DHH Protein